✨ Free AI Report
Guardant Health, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Guardant Health, Inc.
Company Research

Guardant Health, Inc.: Business Overview, Financials & Competitive Analysis

Guardant Health, Inc. scores 8/10 on the AskCyborg Cyborg Score (Strong). Guardant Health is a high-growth precision oncology leader benefiting from FDA approvals, expanding reimbursement, and strategic partnerships in liquid biopsy cancer detection. With a market capitalization of $13.6B and trailing twelve month revenue of $903M, Guardant Health demonstrates strong market position and rapid growth. In 2024, Guardant Health's revenue.

What is Guardant Health, Inc.'s industry? Guardant Health, Inc. (guardanthealth.com) operates in Precision Oncology & Liquid Biopsy Diagnostics. AskCyborg classifies Guardant Health, Inc. under Precision Oncology & Liquid Biopsy Diagnostics in its company registry.

Guardant Health is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FD...

8/ 10Strong

Cyborg Score thesis

Guardant Health is a high-growth precision oncology leader benefiting from FDA approvals, expanding reimbursement, and strategic...

Read the full analyst-debate transcript →
Industry Precision Oncology & Liquid Biopsy Diagnostics
4 named competitors
4 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: November 2, 2026
AI-Generated Research
30+ Page Report

Get the Latest Guardant Health, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Guardant Health, Inc.

AskCyborg analysts argue the bull and bear cases for Guardant Health, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Guardant Health, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Guardant Health, Inc. Overview

Pro stress-test →

Guardant Health is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research.

Strategic Profile

Pro stress-test →

In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. The company is positioned at the intersection of precision oncology and diagnostic innovation, with recent strategic partnerships like the multi-year collaboration with Merck announced in January 2026. Clinical validation, regulatory wins, and operational efficiencies are improving reimbursement prospects and accelerating the company's path to profitability.

Competitive Landscape

Pro stress-test →

Exact Sciences is one of Guardant Health's main competitors. The company operates in the precision oncology and liquid biopsy space alongside players like Natera and Illumina. Illumina and Guardant Health settled their dispute in 2023, signed a long-term supply agreement, and agreed to share specimen samples for cancer research.

Industry Context

Guardant Health, Inc. operates in Precision Oncology & Liquid Biopsy Diagnostics.

Key facts

Founded: 2012 · Headquarters: Palo Alto, US · Employees: ~1,400 · Revenue: $903M · Market cap: $13.6B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Guardant Health, Inc..

  • Multi-year strategic collaboration agreement announced with Merck (January 2026) to develop companion diagnostics using Guardant Infinity Smart Platform
  • FDA approval for Shield liquid biopsy for colorectal cancer screening (2024)
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • January 2026Multi-year strategic collaboration with Merck for companion diagnostics development
  • January 2026FDA approval for Guardant360 CDx as companion diagnostic for BRAFTOVI combination therapy
  • +2 moreTrack every material event for Guardant Health, Inc. as it happens. Explore monitoring →
Get alerted when Guardant Health, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Exact SciencesPrecision oncology and cancer screening tests→NateraGenetic testing and liquid biopsy solutions→Foundation MedicineMolecular oncology testing services→IlluminaDNA sequencing and genomic analysis→

Compare Guardant Health, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Guardant Health, Inc. operates in Precision Oncology & Liquid Biopsy Diagnostics. See how the rest of the sector scores on the Cyborg framework.

Browse Precision Oncology & Liquid Biopsy Diagnostics research →
NEW · MCP server

Ask your AI assistant about Guardant Health, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Guardant Health, Inc. and its top competitor on Cyborg Score”
“What did Guardant Health, Inc. do this quarter?”
“Is Guardant Health, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com (you must copy support@askcyborg.com) · Terms of Service

Frequently asked questions

What does Guardant Health, Inc. do?+
Guardant Health is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FD...
What is Guardant Health, Inc.'s Cyborg Score?+
Guardant Health, Inc. has a Cyborg Score of 8/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Guardant Health, Inc.'s main competitors?+
Named competitors include Exact Sciences, Natera, Foundation Medicine, Illumina. The full competitive landscape is in the AskCyborg report.
How can I get the full Guardant Health, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Guardant Health, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Guardant Health, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Precision Oncology & Liquid Biopsy Diagnostics research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Guardant Health, Inc.8Natera, Inc.6Illumina, Inc.